

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

## Testosterone eliminates strategic prosocial behavior

Hana H. Kutlikova<sup>\*a</sup>

Lei Zhang<sup>a</sup>

Christoph Eisenegger<sup>a †</sup>

Jack van Honk<sup>b,c</sup>

Claus Lamm<sup>a,d</sup>

<sup>a</sup> Department of Cognition, Emotion, and Methods in Psychology, University of Vienna, Vienna 1010, Austria

<sup>b</sup> Department of Experimental Psychology, Helmholtz Institute, Utrecht University, Utrecht 3584 CS, the Netherlands

<sup>c</sup> Department of Psychiatry and Mental Health, University of Cape Town, Cape Town 7701, South Africa

<sup>d</sup> Vienna Cognitive Science Hub, University of Vienna, Vienna 1010, Austria

<sup>†</sup> Deceased February 27, 2017

\*Corresponding author: Hana H. Kutlikova, Liebiggasse 5, University of Vienna, Vienna 1010, Austria, [hana.kutlikova@univie.ac.at](mailto:hana.kutlikova@univie.ac.at), +421 902 300 678

**Author Contributions:** H.H.K. and L.Z. share the first authorship of this article. H.H.K., C.E., and CL designed research; H.H.K. performed research; H.H.K. and L.Z. analyzed data; H.H.K., L.Z., C.L., and J.v.H. wrote the paper.

**Competing Interest Statement:** The authors declare no competing interest.

49 **Abstract**

50 Humans are strategically more prosocial when their actions are being watched than when they act  
51 alone. Using a psychopharmacogenetic approach, we investigated the computational and  
52 endocrinological mechanisms of such audience-driven prosociality. 187 participants received either a  
53 single dose of testosterone or a placebo and performed a prosocial and self-oriented reinforcement  
54 learning task. Crucially, the task was performed either in private or when being watched.  
55 Rival theories of testosterone's role in status-seeking suggest that the hormone might either strengthen  
56 or diminish audience-dependent generosity. We show that exogenous testosterone strongly decreases  
57 submission to audience expectations, fully eliminating strategic i.e., feigned generosity. We next  
58 performed reinforcement-learning drift-diffusion modeling to elucidate which latent aspects of  
59 decision-making testosterone acted on. Computational modeling revealed that testosterone compared  
60 to placebo did not deteriorate reinforcement learning per se, rather, in presence of the audience, the  
61 hormone impacted the expression of the learned information into behavioral choice. These results  
62 indicate that instead of deceptively increasing socially desirable behavior, testosterone boosts honest  
63 forms of status-seeking, arguably by impacting the motivational link between learned values and  
64 behavior.

65

66

67 **Keywords:** testosterone, prosocial behavior, audience-effect, reinforcement learning, drift-diffusion  
68 model

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

## 84 Introduction

85 Humans behave more prosocially when their actions are watched by others<sup>1</sup>. This  
86 phenomenon has been demonstrated across a variety of social behaviors, such as blood donations<sup>2</sup>,  
87 church offerings<sup>3</sup>, or monetary donations to charitable organizations<sup>4</sup>, and is often referred to as  
88 strategic prosociality<sup>5</sup> or the audience effect<sup>6</sup>. From an evolutionary perspective, making one's  
89 generosity visible to others has an important signaling value, in that it advertises an individual's  
90 qualities as a potential partner or a valuable group member<sup>7</sup>. In the present study, we propose and  
91 investigate whether the steroid hormone testosterone plays a crucial role in such audience effects.

92 Research in the past decade has demonstrated that testosterone is implicated in a wide  
93 spectrum of socially dominant behaviors<sup>8,9</sup>. Exogenous testosterone alleviates subordination to the  
94 dominance of others<sup>10-12</sup> and reduces the physiological stress response to being evaluated by others<sup>13</sup>.  
95 Given that enhanced submission to audience expectations has been associated with increased social  
96 anxiety and an intense apprehension about social evaluation<sup>14</sup>, testosterone administration might  
97 decrease audience effects.

98 In contrast, the hypothesis that testosterone drives status-seeking via reputation building  
99 rather than dominance<sup>15,16</sup> would predict that based on the social context, testosterone might  
100 conditionally promote prosocial and especially socially desirable behavior to build up a reputation  
101 and increase status. The present paper is the first that aimed to distinguish between these two  
102 alternatives of boosting one's social status that testosterone may act on. One option is that, in line with  
103 the social dominance hypothesis<sup>17</sup>, the hormone prioritizes dominant status-seeking and would hence  
104 diminish the submission to audience expectation. The other option is that testosterone primarily  
105 promotes reputable status-seeking<sup>15,16</sup>. If true, the hormone could increase strategic prosocial  
106 behavior.

107 Through what neurobiological pathways could testosterone modulate such complex social  
108 behaviors? Previously, exogenous testosterone was found to increase dopamine levels in the rat  
109 ventral striatum<sup>18</sup>, suggesting that the hormone exerts its effects through modulation of dopaminergic  
110 activity in reward-related neural circuits. Besides this insight from animal research, testosterone and  
111 reward processing have also been linked in humans<sup>19,20</sup>. It remains to be shown, though, which  
112 specific aspects of reward processing testosterone acts on. For one, during value learning, testosterone  
113 may influence the incorporation of the so-called reward prediction errors (RPE) which track the  
114 difference between predicted and actual outcome<sup>21</sup> and are encoded by the phasic activity of midbrain  
115 dopaminergic neurons projecting to the ventral striatum<sup>22,23</sup>. Alternatively, testosterone may impact  
116 the conversion of the learned values into choice performance, or the temporal dynamic of the  
117 evidence accumulation.

118 The present study thus not only aimed to investigate if testosterone influences strategic  
119 prosociality, but also whether this is achieved by impacting reward-related computations. We

120 employed a novel modeling approach, by combining reinforcement learning with diffusion decision  
121 models (RLDDM). This provided a more comprehensive account of the latent processes involved in  
122 prosocial decision-making than previous separate RL and DDM approaches<sup>21,24</sup>. Besides describing  
123 how subjective values of the choice options are learned through RPEs (*learning rate parameters*) and  
124 converted to actions (*choice consistency parameter*), the new combination of reinforcement learning  
125 and diffusion decision modeling also enabled us to explore the temporal dynamics of these latent  
126 processes (*decision threshold and drift-scaling parameters*, see *SI Table S3* for parameter  
127 description)<sup>24</sup>.


128 Male participants ( $n = 187$ ) underwent a double-blind, between-subject, placebo-controlled,  
129 topical testosterone (150 mg) administration and then performed a reinforcement learning task (Figure  
130 1). On each trial, participants were required to choose between one of two symbols. One symbol was  
131 associated with a high probability (75%), and one was associated with a low probability (25%) of a  
132 reward. These contingencies were not instructed but had to be learned through trial and error. While  
133 classic charitable donation tasks<sup>16</sup> and neuroeconomic games<sup>8,9</sup> overtly measure participants' overall  
134 prosociality, the RL task allowed us to furthermore characterize the hidden individual steps in the  
135 process of learning about the consequences actions have for oneself and others. To compare self- and  
136 other-oriented decision-making, participants completed the task for themselves and for an NGO of  
137 their choice (within-subject condition). Critically, the task was performed either in private or when  
138 being watched (between-subject condition, see *Materials and Methods*).

139 Based on previous audience-effect research<sup>2-6</sup>, we predicted that when the participants are  
140 watched, they will be relatively more prosocial (i.e., make more correct choices for the other vs self)  
141 than in private. Crucially, we expected that such an audience effect will be underpinned by relatively  
142 faster incorporation of RPEs (learning rate parameter  $\alpha$  in RL); higher consistency in converting  
143 values to action probability, (inverse temperature parameter  $\tau$  in RL, also known as value  
144 sensitivity, exploration parameter, or  $1/\beta$ ); and more integrated evidence necessary for making a  
145 decision (threshold parameter in DDM). In other words, participants would learn more efficiently,  
146 learned values would inform their behavior more consistently, and their decisions would be more  
147 cautious.

148 Our main hypothesis was that the effects of being watched on other- vs. self-benefitting  
149 behavior will be modulated by testosterone administration. Given that testosterone reduces  
150 submission signals and stress response to the social evaluation, allowing for dominant status-  
151 seeking<sup>10-13</sup>, we hypothesized that testosterone would reduce the audience effect expected in the  
152 placebo group. As an alternative prediction, we reasoned that if testosterone does not primarily cause  
153 dominant status-seeking, but instead, in non-threatening environments, promotes more agreeable  
154 reputable status-enhancing behaviors<sup>16,17</sup>, participants in the testosterone (vs placebo) group should  
155 show a larger audience effect. Irrespective of whether testosterone would increase or decrease

156 prosocial behavior under the audience effect, we also predicted that testosterone's effects will be  
 157 associated with changes in the efficiency of RPE-based value updating ( $\alpha$  in RL), choice consistency  
 158 ( $\tau$  in RL), and evidence necessary for making a decision (threshold parameter in DDM).

159 Furthermore, considering that testosterone possibly modulates social behavior through both  
 160 androgenic and dopaminergic pathways<sup>25</sup>, we explored whether a CAG repeat polymorphism of the  
 161 androgen receptor, as well as a DAT1 polymorphism of the dopamine transporter, interacts with  
 162 testosterone administration effects. Finally, as it has been suggested that sensitivity of dopaminergic  
 163 pathways is heightened among highly dominant individuals<sup>26</sup> and that these individuals show more  
 164 pronounced effects of testosterone administration<sup>25,27</sup>, we as well tested whether testosterone effects  
 165 on strategic prosociality vary as a function of self-reported trait dominance<sup>28</sup>.




166 **Figure 1.** Experimental design and task. (A) Timeline of the experimental session. (B) Prosocial reinforcement  
 167 learning task. Participants performed the task either in private or watched by an observer introduced as an NGO  
 168 association representative. The observation was signalled by a red frame. Each participant completed three  
 169 blocks of 16 trials for themselves and three blocks of 16 trials to benefit an NGO of his choice. (C) Schematic of  
 170 the reinforcement learning drift diffusion model (RLDDM). Left panel: trial-by-trial value updates in RL; right  
 171 panel: evidence accumulation in DDM. Importantly, the drift rate in DDM is calculated from the value  
 172 difference between choice options in RL.

## 173 Results

### 174 Testosterone eliminates the audience effect

175 After having confirmed that the testosterone administration produced a clear increase in the salivary  
176 testosterone levels of the treatment compared to the placebo group (drug treatment x time:  
177  $F(3,522.59) = 47.82, p < .001, \eta^2 p = .423$ , see *SI: Supplementary analysis of hormone data*), we  
178 analyzed the effects of drug treatment (P/T), visibility (private/observed), and type of recipient  
179 (self/other) on the number of correct choices (i.e., options that have higher reward probability). The  
180 three-way interaction of these factors was found to predict the number of correct choices ( $OR = 1.06$ ,  
181  $CI = [1.00, 1.13], p = .046$ ; Figure 2A). Follow-up analysis using treatment contrasts showed that  
182 participants in the placebo group showed more prosocial behavior, as indicated by relatively more  
183 correct prosocial choices, when being watched compared to the private setting in which they were not  
184 watched (recipient x visibility interaction in placebo group:  $OR = 1.44, CI = [1.02, 2.02], p = .039$ ).  
185 Supporting our prediction based on the social dominance hypothesis, this audience effect was absent  
186 in the testosterone group (recipient x visibility interaction in testosterone group:  $OR = 0.88, CI =$   
187  $[0.63, 1.23], p = .461$ ). Specifically, when participants were observed, testosterone, compared to  
188 placebo, reduced the number of correct choices made for another ( $OR = 0.67, CI = [0.49, 0.91], p$   
189  $= .011$ , Figure 2C). The number of correct choices made for self, however, was not influenced by the  
190 drug treatment ( $OR = 1.12, CI = [0.87, 1.45], p = .384$ ), visibility ( $OR = 0.98, CI = [0.75, 1.27], p$   
191  $= .861$ , or their interaction ( $OR = 0.91, CI = [0.63, 1.33], p = .638$ , (Figure 2B).



192

193 **Figure 2.** The differences in the number of correct choices. (A) Participants in the placebo group behaved more  
194 prosocially (as measured by prosociality index = correct choices for other – correct choices for self) when being  
195 observed than in privacy. Exogenous testosterone eliminated this audience effect. (B) Pairwise comparisons  
196 showed that there was no significant effect of the experimental groups on the number of correct choices made  
197 for oneself. (C) Testosterone, compared to placebo, decreased the number of correct choices made for the NGO  
198 when being observed. Dots represent the data of individual participants, lines represent mean values per group,  
199 and bands 95% confidence intervals.

200

201 **Behavior is best explained by a reinforcement learning drift diffusion model with positive and**  
202 **negative learning rates**

203 Next, we sought to uncover the computational mechanisms underlying the experiment-condition-  
204 specific behavioral differences on a trial-by-trial basis. The winning model (winning over five other  
205 candidate models; see *Materials and Methods* and *SI: Model selection and validation*) entailed  
206 combined RL and DDM component, thus simultaneously predicted individuals' choices and RTs (see  
207 *SI: Table S3* for a complete list of parameters and their description). The RL component section  
208 predicted participants' learning behavior via the value updates through the computation of RPEs with  
209 separate positive and negative learning rates (i.e.,  $\alpha^{\text{pos}}$  and  $\alpha^{\text{neg}}$  Equation (1)). In other words, the  
210 model that best accounted for the data assumed a differential speed of learning with and without  
211 positive feedback:

$$212 \quad V_{c,t} = \begin{cases} V_{c,t-1} + \alpha^{\text{pos}} (O_{t-1} - V_{c,t-1}), & \text{if } O_{t-1} > 0 \\ V_{c,t-1} + \alpha^{\text{neg}} (O_{t-1} - V_{c,t-1}), & \text{otherwise} \end{cases} \quad (1)$$

213 where  $O_{t-1}$  denotes the outcome, and  $V_{c,t-1}$  the subjective value of choice  $c$  at trial  $t - 1$ .

214 In addition, the DDM component predicted RTs by assuming an evidence accumulation process (as  
215 quantified by the drift rate; decisions were made when the evidence reached a certain threshold<sup>29</sup>).

216 Importantly, the marriage between RL and DDM allowed a fine-grained investigation into how the  
217 drift rate ( $v_t$ ) was shaped by the value difference between two symbols at the trial-by-trial level  
218 (Equation (2);  $S$ , a non-linear transformation function;  $v_{\text{scaling}}$ , a weight parameter that maps accuracy-  
219 coded value difference into the drift rate<sup>24</sup>).

$$220 \quad v_t = S[v_{\text{scaling}} (V_{\text{correct},t} - V_{\text{incorrect},t})], \quad (2)$$

221 We fitted all candidate models (see *Materials and Methods* and *SI: Supplementary information on*  
222 *computational modeling*) under the hierarchical Bayesian estimation scheme<sup>30</sup> to incorporate both  
223 group-level commonality and individual differences, according to our task design (effects of drug  
224 treatment (P/T), visibility (private/observed), and type of recipient (self/other)).

225

226 **Testosterone's impact on strategic prosocial behavior is associated with choice consistency**

227 Next, we investigated which RLDDM parameters of our validated winning model are associated with  
228 the effects found in the behavioral analysis of the correct choice. As a first step, we tested the  
229 parameters for the 3-way interaction effect of drug treatment, visibility, and type of recipient.

230 In the second step, we examined whether the parameters that showed a three-way interaction effect of  
231 our experimental manipulation predict behavioral prosociality. Behavioral prosociality was measured  
232 by the difference between correct choices made for others and self.

233 Out of the five parameters (positive and negative learning rate, choice consistency, threshold, drift-  
234 scaling parameter) only choice consistency showed the three-way interaction of our experimental



235 manipulations ( $B = 0.98$ ,  $CI = [0.97, 0.99]$ ,  $p < .001$ ), and at the same time significantly predicted  
236 behavioral prosociality (Bonferroni correction for multiple comparisons,  $B = 5.45$ ,  $CI = [3.71, 7.19]$ ,  $p$   
237  $< .001$ ; Figure 3D). Specifically, the placebo group participants had relatively higher consistency in  
238 choices made for the other (vs. self) when being observed than in privacy (recipient x visibility  
239 interaction in the placebo group:  $B = 1.08$ ,  $CI = [1.05, 1.10]$ ,  $p < .001$ ). On the contrary, in the  
240 testosterone group, observation, compared to privacy, decreased the consistency of choices made for  
241 the other (vs. self) (recipient x visibility interaction in testosterone group:  $B = 0.94$ ,  $CI = [0.92, 0.97]$ ,  
242  $p < .001$ ; Figure 3B). When participants were observed, testosterone, compared to placebo,  
243 diminished the relative consistency of prosocial choices (recipient x treatment interaction in observed  
244 condition:  $OR = 0.87$ ,  $CI = [0.85, 0.89]$ ,  $p = .001$ ). In the private condition, there was no evidence for  
245 such an effect (recipient x treatment interaction in private condition:  $OR = 0.99$ ,  $CI = [0.97, 1.02]$ ,  $p$   
246  $= .605$ ; for analysis of all RLDDM parameters, see *SI: Analysis of the RLDDM parameters and their*  
247 *association with prosocial behavior*).  
248 Altogether, these results suggest that testosterone eliminates audience-dependent prosocial behavior  
249 by affecting choice consistency.

250

### 251 **Interaction of testosterone effects with trait dominance and genetic polymorphisms**

252 In further support of the social dominance hypothesis, trait dominance interacted with testosterone's  
253 effects on correct choice (recipient x drug treatment x visibility x trait dominance:  $OR = 1.04$ ,  $CI =$   
254  $[1.01, 1.09]$ ,  $p = .026$ ). Decomposition of this four-way interaction revealed that testosterone reduced  
255 the number of correct choices made for others during observation specifically among men with high  
256 trait dominance ( $OR = 0.60$ ,  $CI = [0.42, 0.87]$ ,  $p = .008$ ) and this effect was weaker and non-  
257 significant among those with low dominance ( $OR = 0.74$ ,  $CI = [0.52, 1.04]$ ,  $p = .084$ ). Trait  
258 dominance did not significantly interact with the RLDDM parameters (all  $ps > .220$  see *SI: Interaction*  
259 *of trait dominance with testosterone effects on RLDDM parameters*).

260 CAG-repeat and DAT1 polymorphisms did not interact with the effects of testosterone on correct  
261 choice or RLDDM parameters (all  $ps > .090$ , see *SI: Supplementary information on the analysis of*  
262 *genetic data*).

263

### 264 **Learning parameters in relation to optimal learning rates**

265 To gain a deeper understanding of how the learning parameters were related to the task performance  
266 in our experimental design, we performed a simulation study to identify optimal learning rates<sup>31</sup> (see  
267 *SI: Simulations of optimal learning rates*). In all conditions, both the posterior positive and negative  
268 learning rates were smaller with respect to the optimal ones (see Figure 4A, 4C). Crucially, to validate  
269 whether the choice accuracy corresponding to the posterior parameters in our winning model could  
270 capture key patterns in our behavior findings (i.e., posterior predictive check), we let our winning



271 model generate synthetic data and analyzed the generated prosocial behavior (i.e., choice accuracy for  
 272 other minus choice accuracy for self) in the same way as we analyzed the observed data. We found  
 273 that results from the generated data (Figure 4B, 4D) greatly resembled the behavioral patterns  
 274 reported in Figure 2A.

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304


305

306


307

308

309



**Figure 3.** The differences in the parameters estimated by the reinforcement learning drift diffusion model (RLDDM). (A) In the placebo group, observation compared to privacy relatively decreased the prosocial negative learning rate (i.e., the difference between negative learning rates in the other condition and the self condition). Testosterone administration reversed the observation effect. The results suggest that for better performance in the task, a lower negative learning rate is more suitable. (B) In the placebo group, observation compared to privacy, relatively increased the consistency of the prosocial choices. Testosterone administration reversed this audience effect. (C) In the placebo group, observation compared to privacy, relatively increased the DDM threshold for prosocial choices. Testosterone administration reversed the audience effect. (D) Inverse temperature parameter  $\tau$  that captures choice consistency significantly predicted prosociality. Dots represent the data of individual participants, lines represent mean values per group, and bands 95% confidence intervals.



310

311 **Figure 4. Optimal learning rates and posterior predictive checks.** Posterior learning rates in relation to the  
 312 optimal learning rates in the private (A) and observed (C) conditions. Orange dots represent the optimal  
 313 combination between positive and negative learning rates identified via simulation; red crosses indicate the  
 314 posterior means of learning rates. The posterior learning rates were employed to perform posterior predictive  
 315 checks for the main behavioral findings for the private (B) and observed (D) conditions. Simulated data from  
 316 posteriors were analyzed in the similar fashion as the real data and the model prediction largely matched our  
 317 main behavioral effect (cf. Figure 2A).

318

## 319 Discussion

320

321 Using pharmacological manipulation and a novel computational model integrating  
 322 reinforcement learning with the drift diffusion modeling (RLDDM) framework, we tested and  
 323 characterized testosterone's role in the audience-dependent prosocial behavior. The results show that  
 324 testosterone diminishes the typical audience effect present in the placebo condition. Computational  
 325 modeling pinpoints this effect to a reduction in the extent to which the performance of prosocial (vs.  
 326 selfish) choices are consistent with learned reward values. Moreover, the effects are more pronounced  
 327 in participants with higher trait dominance. Taken together, these findings are in line with the social  
 328 dominance hypothesis, and are thus consistent with the notion that testosterone decreases submission  
 to audience expectations, rather than promoting the strategic display of socially pleasing behavior<sup>32,33</sup>.

329           A growing body of evidence suggests that testosterone exerts its behavioral effects through  
330 the modulation of reward-related processes<sup>19,20</sup>. However, to our knowledge, no study investigated the  
331 computational mechanisms underlying such effects. Using joint RLDDMs, we found that in the  
332 placebo group, observation (vs privacy) increased the relative consistency of prosocial choices.  
333 Testosterone administration eliminated this audience effect, making the performance of prosocial (vs.  
334 self) choices less consistent with value computations. Low choice consistency means that individuals  
335 select options with non-maximal expected values, which is often referred to as exploratory behavior<sup>34</sup>.  
336 In environments with static reward probabilities, participants can maximize their reward by initially  
337 exploring which option tends to be more fruitful. Once learners discover the better option, exploration  
338 yields no benefit. One possible explanation of the present effect could therefore be that testosterone  
339 impaired individuals' ability to adapt and control the amount of exploration. However, our data do not  
340 indicate that testosterone affects exploration in general, as we did not find any testosterone influence  
341 on choice consistency in the private setting.

342           Rather, the present testosterone's effect appears to be dependent on the social context and  
343 manifests only in the environment where one is watched by others. What processes could channel the  
344 context-specific effects of testosterone? We propose that testosterone's elimination of the audience  
345 effect stems from the hormone's ability to reduce fear in social situations. Indeed, earlier research  
346 shows that exogenous testosterone diminishes the physiological stress response to the presence of an  
347 observer<sup>12</sup> and has anxiolytic-like properties in humans and across species<sup>10,35,36</sup>. Importantly, anxiety  
348 and stress were reported to inversely correlate with exploratory behavior<sup>37,38</sup>. Moreover, social anxiety  
349 levels positively predict prosocial behavior performed while being watched<sup>14</sup>. It is thus plausible that  
350 the participants in the testosterone condition who were watched were, compared to the placebo group,  
351 less motivated to exert increased prosocial effort necessary to fulfill the audience expectations.  
352 Instead, they engaged in less demanding exploratory behavior.

353           Drawing on the distinction between social dominance and favorable reputation as two  
354 evolutionarily grounded routes for attaining status in social systems across species<sup>28</sup>,  
355 our study suggests that although socially desirable behavior may be a road to leadership in human  
356 democratic societies, testosterone does not promote such pleasing strategies<sup>32</sup>. Consistent with this,  
357 our analysis shows that testosterone eliminates strategic prosociality particularly among individuals  
358 with high trait dominance. Variability in dominance and cultural differences in social status  
359 attainment can also account for the results of another recent study, which was conducted among  
360 Chinese students and showed that testosterone enhanced audience effects<sup>16</sup>. Indeed, contrary to  
361 western society, in eastern cultures, high social status is associated with increased other-orientation,  
362 including generosity and benevolence to those with lower status<sup>39</sup>. These cultural differences have  
363 been linked to polymorphisms in the dopamine D4 receptor gene<sup>40</sup>, implying a putative biological  
364 mechanism that could explain cultural differences in testosterone effects.

365 Our results are, furthermore, in line with studies showing that testosterone decreases  
366 deception<sup>41-43</sup>. Further research is, however, needed to determine whether testosterone reduces lying  
367 per se, or only in the situations, in which dishonest behavior may be considered “cheap”, dishonorable  
368 and lower the subject’s feelings of pride and self-image<sup>41</sup>.

369 There are also some limitations inherent to the methodology of our study. Due to the sex  
370 differences in testosterone metabolism and unknown pharmacokinetics following the topical  
371 administration of testosterone in women<sup>44</sup>, the study included only male participants. Hence, the  
372 generalization of these findings to females requires further investigation.

373 Crucial for advancing our understanding of the relationship between testosterone, dominance,  
374 and status-seeking is the investigation of the pathways through which testosterone exerts its effects.  
375 We conducted a multifaceted examination of the computational, endocrinological, and genetic  
376 mechanisms underlying audience effect and showed that testosterone reduced strategic prosocial  
377 learning through impairment of choice consistency. These findings provide the first evidence that in  
378 the Western student sample, testosterone abolishes audience effects, and therefore does not foster  
379 seeking of social leadership by reputational politics. Furthermore, this study reveals that testosterone  
380 impacts status-seeking by influencing how the learned values are expressed in behavior.

## 381 **Materials and Methods**

### 382 **Participants**

383  
384 The study sample consisted of 192 healthy adult men aged between 18 and 40 years ( $M = 24.89$ ,  $SD =$   
385  $4.08$ ). The sample size was determined based on previous testosterone administration studies (8, 32)  
386 and our pilot study. Our sample size gave us 90% power to detect relatively small effects of size  $f \geq$   
387  $0.15$ , for the main analyses of interest (i.e., interaction effects of the factors drug treatment, visibility,  
388 and type of recipient on the RLDDM parameters). Participants were recruited via flyers placed around  
389 university campuses and online advertisements. The volunteers, who replied to these advertisements,  
390 were screened via an online questionnaire and a telephone interview. The exclusion criteria comprised  
391 a history of neurological or psychiatric disorders, endocrine or other internal diseases, obesity,  
392 substance dependence, and the use of steroids. Only male participants were included as testosterone  
393 metabolism is subject to sex differences and the pharmacokinetics of topical administration of  
394 testosterone are unclear in women<sup>44</sup>. Three participants were excluded because of an unreliable  
395 change in hormone levels (see *SI: Supplementary analysis of hormone data*) and two participants  
396 were excluded because they continually clicked on the same response key irrespective of changing  
397 stimuli and reward probabilities for more than 80% of the block trials, and thus were classified as  
398 non-compliant. All participants gave written consent and received a financial reward for their  
399 participation consisting of a flat fee and a bonus based on their task performance. All procedures were  
400 approved by the local research ethics board and conducted following the latest revision of the  
401 Declaration of Helsinki<sup>45</sup>.

### 403 **Procedure and experimental conditions**

404 Testing took place in groups of three to five participants, who were seated individually in small  
405 cubicles within the same testing room. All experimental sessions started between 01:00 and 02:30  
406 p.m. First, a buccal smear sample for CAG repeat and DAT1 polymorphisms analysis was taken (See  
407 *SI: Supplementary information on the analysis of genetic data*). 20 min after arrival, participants were  
408 asked to drool 2 mL of saliva into a polyethylene collection tube. All salivary samples were frozen  
409 on-site and stored at - 30 °C until analysis. Afterward, participants were administered topical  
410 testosterone or placebo gel in a double-blind between-subjects design with random group allocation.  
411 Those allocated to the testosterone group received a single dose of testosterone gel, containing 150  
412 mg testosterone [AndroGel®]; participants in the placebo group received an equivalent amount of  
413 placebo gel. The only difference between the testosterone and placebo gel was that the placebo gel did  
414 not contain testosterone. Participants rubbed the gel onto their upper arms and shoulders using  
415 disposable latex gloves. Gel administration was followed by a 2-hour waiting period, during which  
416 participants remained in the laboratory premises, completed the Dominance-Prestige Scale<sup>28</sup> and  
417 demographic questionnaires, and were offered leisure-time reading materials. One hour and 50  
418 minutes after the gel application, participants provided a second saliva sample and subsequently  
419 began the experimental task (see Figure 1). Two more saliva samples were taken during the course of  
420 the study: 20 and 60 minutes after the end of the experimental task. After data collection was  
421 complete, saliva samples were analyzed by liquid chromatography-tandem mass spectrometry in  
422 Dresden LabService GmbH, Germany.

423 Participants performed the task under one of the two randomly assigned between-subject conditions,  
424 either in private or when being observed. In the private condition, participants were informed that  
425 their task performance is completely anonymous and no one (including the experimenter) would know  
426 how much money they would earn for themselves and the charitable organization. In the observed  
427 condition, two female observers, introduced as NGO association representatives entered the room and  
428 watched participants perform the task. The observers were seated at a desk with a laptop and had an  
429 equal view of all the participants. In addition, when participants were observed, a red frame was  
430 shown on their computer's screen and the displays of the participants' computers were transmitted  
431 onto the observers' laptop screens.

432 Participants were thus randomly assigned into four experimental groups corresponding to the levels of  
433 two between-subject factors: (1) treatment (testosterone/placebo) and (2) visibility (observed/private).  
434 These groups did not differ in age, trait dominance, basal hormone levels, or distribution of AR CAG  
435 and DAT1 genotype (see *SI: Table SI*).

### 436 **Prosocial learning task**

437 Participants performed a probabilistic reinforcement learning task<sup>46</sup>, where they could earn rewards  
438 either for themselves (self condition) or for an NGO of their choice (other condition). On each trial,  
439 participants were presented with two abstract symbols, one associated with a high (75%) and the other



440 with a low (25%) reward probability. These contingencies were not instructed but had to be learned  
441 through trial and error. Participants selected a symbol by a button press and then received feedback on  
442 whether they obtained points or not. This way participants learned which symbol to choose to  
443 maximize the rewards in the long run. The points were converted to monetary rewards at the end of  
444 the experiment. Participants completed 6 blocks, 3 blocks in self and 3 blocks in the other condition.  
445 Each block started with a new pair of symbols and consisted of 16 trials/choices. Block with the same  
446 recipient did not occur twice in a row. In self condition, the blocks started with “YOU” displayed and  
447 had the word “YOU” at the top of each screen. In the other condition, the blocks started with “NGO”  
448 displayed and had the word “NGO” at the top of each screen. At the end of the experimental task,  
449 participants could choose the recipient of the money they earned in the other condition from a list of 6  
450 different charities.

#### 451 **Statistical analysis of correct choices**

452 Statistical analysis was performed using R statistical language<sup>47</sup>. We analyzed the treatment  
453 (testosterone/placebo) x visibility (observed/private) x recipient (self/other) interaction effect on  
454 correct choice using generalized linear mixed models (GzLMM) with binomial distribution and logit  
455 link function<sup>48</sup>. The correct choice was defined as choosing the symbol with a higher reward  
456 probability. Participant’s identity was modeled as a random intercept effect and the within-subject  
457 factor recipient (self/other) was entered as a random slope.

458 To examine whether the effects of testosterone on correct choice varied as a function of trait  
459 dominance, CAG repeat, and DAT1 polymorphism, we added these variables separately as predictors  
460 in interaction with the other factors specified in the above GzLMM. In case of the significant  
461 interaction of trait dominance with testosterone effects on the correct choice, we conducted a follow-  
462 up analysis, where the continuous measure of dominance was replaced by a categorical variable with  
463 levels of high and low dominance, based on the median split of dominance scores (Med = 3.875).

464 P-values were based on Type III Wald chi-square tests from the R car package, post-hoc tests of  
465 significant three-way interactions were conducted with the R sjPlot package that provided reported  
466 odds ratios (ORs) together with 95% confidence intervals (95% CIs). Plots were created using yarr  
467 and ggplot2 R packages (See *SI* for references).

#### 468 **Reinforcement learning drift-diffusion modeling**

469 To uncover the cognitive computational processes underlying our learning task, we performed  
470 modeling analysis under the joint reinforcement learning drift diffusion model (RLDDM)  
471 framework<sup>24,29</sup>. In essence, RLDDM bridges RL, which typically models choices, and DDM, which  
472 commonly models response times (RT). This approach has been proven to provide more granularity  
473 than using RL or DDM alone<sup>24</sup>. We tested 6 candidate RLDDM models and the winning model is

474 described below (see *SI: Supplementary information on computational modeling* for full model  
475 description, estimation, and comparison procedures).  
476 The RL part of the winning RLDDM model was implemented with a reward-punishment simple  
477 reinforcement learning model, where both a positive learning rate and a negative learning rate were  
478 employed to update values (i.e.,  $V(A)$  and  $V(B)$  for two-choice options) through the computation of  
479 RPEs<sup>49</sup> (Equation (1); see also *SI: Supplementary information on computational modeling*).  
480 The DDM part of the winning RLDDM model was implemented via a non-linear transformation of  
481 the accuracy-codded value differences computed from the RL counterpart, to construct the trial-by-  
482 trial drift rates<sup>24</sup> (Equation (2); see also *SI: Supplementary information on computational modeling*).  
483 The winning model contained 14 parameters: 7 separate parameters for each between-subject  
484 condition (i.e., placebo/testosterone, private/observed), and differential parameters for the within-  
485 subject condition (i.e. other/self; see *SI: Table S3* for the parameter list and description).

#### 486 **Statistical analysis of model parameters**

487 The drug treatment (testosterone/placebo) x visibility (observed/private) x recipient (other/self) effect  
488 on the extracted free parameters was analyzed using GzLMMs analogous to the analysis of the correct  
489 choice. Due to the non-normal distribution of residuals, gamma distribution with a log link function  
490 was used for the parameter analyses. Finally, we tested whether the RLDDM parameter estimates, that  
491 were affected by the interaction of the drug treatment, visibility, and recipient could explain the  
492 differences observed in the behavioral prosociality measure. To do so, we conducted multiple linear  
493 regressions with the difference in the number of correct choices made for another and self  
494 (*prosociality index*) as a dependent variable and the differences in the RLDDM parameter estimates  
495 ( $\alpha_{\text{neg}_{\text{other}}} - \alpha_{\text{neg}_{\text{self}}}$ ,  $\tau_{\text{other}} - \tau_{\text{self}}$ ,  $\text{threshold}_{\text{other}} - \text{threshold}_{\text{self}}$ ,  $\text{drift-scaling}_{\text{other}} - \text{drift-scaling}_{\text{self}}$ ) as separate  
496 predictors. Bonferroni correction for multiple comparisons was used.

497

#### 498 **Acknowledgments**

499 We thank Felix Dörflinger and Maximilian Kathofer for their dedicated assistance with data  
500 collection. We also thank Shawn Geniole for his helpful feedback. This work was supported by the  
501 Vienna Science and Technology Fund (WWTF VRG 13-007).

502

503

504

505

506

507

508

509



## 510 References

- 511 1. Bradley A, Lawrence C, Ferguson E. 2018. Does observability affect prosociality?  
512 *Proceedings of the Royal Society B: Biological Sciences* **285**:20180116.  
513 doi:[10.1098/rspb.2018.0116](https://doi.org/10.1098/rspb.2018.0116)
- 514 2. Lacetera N, Macis M. 2010. Social image concerns and prosocial behavior: Field evidence  
515 from a nonlinear incentive scheme. *Journal of Economic Behavior & Organization* **76**:225–  
516 237. doi:[10.1016/j.jebo.2010.08.007](https://doi.org/10.1016/j.jebo.2010.08.007)
- 517 3. Soetevent AR. 2005. Anonymity in giving in a natural context—a field experiment in 30  
518 churches. *Journal of Public Economics* **89**:2301–2323. doi:[10.1016/j.jpubeco.2004.11.002](https://doi.org/10.1016/j.jpubeco.2004.11.002)  
519
- 520 4. Li Y, Météreau E, Obeso I, Butera L, Villeval MC, Dreher J-C. 2020. Endogenous  
521 testosterone is associated with increased striatal response to audience effects during prosocial  
522 choices. *Psychoneuroendocrinology* **122**:104872. doi:[10.1016/j.psyneuen.2020.104872](https://doi.org/10.1016/j.psyneuen.2020.104872)  
523
- 524 5. Böckler A, Tusche A, Singer T. 2016. The Structure of Human Prosociality: Differentiating  
525 Altruistically Motivated, Norm Motivated, Strategically Motivated, and Self-Reported  
526 Prosocial Behavior. *Social Psychological and Personality Science* **7**:530–541.  
527 doi:[10.1177/1948550616639650](https://doi.org/10.1177/1948550616639650)  
528
- 529 6. Hamilton AF de C, Lind F. 2016. Audience effects: what can they tell us about social  
530 neuroscience, theory of mind and autism? *Cult Brain* **4**:159–177. doi:[10.1007/s40167-016-  
531 0044-5](https://doi.org/10.1007/s40167-016-0044-5)  
532
- 533 7. Gintis H, Smith EA, Bowles S. 2001. Costly Signaling and Cooperation. *Journal of*  
534 *Theoretical Biology* **213**:103–119. doi:[10.1006/jtbi.2001.2406](https://doi.org/10.1006/jtbi.2001.2406)  
535
- 536 8. Dreher J-C, Dunne S, Pazderska A, Frodl T, Nolan JJ, O’Doherty JP. 2016. Testosterone  
537 causes both prosocial and antisocial status-enhancing behaviors in human males. *PNAS*  
538 **113**:11633–11638. doi:[10.1073/pnas.1608085113](https://doi.org/10.1073/pnas.1608085113)  
539
- 540 9. Ou J, Wu Y, Hu Y, Gao X, Li H, Tobler PN. 2021. Testosterone reduces generosity through  
541 cortical and subcortical mechanisms. *PNAS* **118**. doi:[10.1073/pnas.2021745118](https://doi.org/10.1073/pnas.2021745118)  
542
- 543 10. Terburg D, Syal S, Rosenberger LA, Heany SJ, Stein DJ, Honk J van. 2016. Testosterone  
544 abolishes implicit subordination in social anxiety. *Psychoneuroendocrinology* **72**:205–211.  
545 doi:[10.1016/j.psyneuen.2016.07.203](https://doi.org/10.1016/j.psyneuen.2016.07.203)  
546
- 547 11. Geniole SN, Proietti V, Bird BM, Ortiz TL, Bonin PL, Goldfarb B, Watson NV, Carré JM.  
548 2019. Testosterone reduces the threat premium in competitive resource division. *Proc Biol Sci*  
549 **286**:20190720. doi:[10.1098/rspb.2019.0720](https://doi.org/10.1098/rspb.2019.0720)  
550
- 551 12. Kutlikova HH, Geniole SN, Eisenegger C, Lamm C, Jocham G, Studer B. 2021. Not giving  
552 up: Testosterone promotes persistence against a stronger opponent.  
553 *Psychoneuroendocrinology* **128**. doi:[10.1016/j.psyneuen.2021.105214](https://doi.org/10.1016/j.psyneuen.2021.105214)  
554
- 555 13. Kutlikova HH, Durdiaková JB, Wagner B, Vlček M, Eisenegger C, Lamm C, Riečanský I.  
556 2020. The effects of testosterone on the physiological response to social and somatic  
557 stressors. *Psychoneuroendocrinology* **117**:104693. doi:[10.1016/j.psyneuen.2020.104693](https://doi.org/10.1016/j.psyneuen.2020.104693)  
558
- 559 14. Cañigueral R, Hamilton AF de C. 2019. Being watched: Effects of an audience on eye gaze  
560 and prosocial behaviour. *Acta Psychol (Amst)* **195**:50–63. doi:[10.1016/j.actpsy.2019.02.002](https://doi.org/10.1016/j.actpsy.2019.02.002)  
561

- 562 15. Eisenegger C, Haushofer J, Fehr E. 2011. The role of testosterone in social interaction. *Trends*  
563 *in Cognitive Sciences* **15**:263–271. doi:[10.1016/j.tics.2011.04.008](https://doi.org/10.1016/j.tics.2011.04.008)  
564
- 565 16. Wu Y, Zhang Y, Ou J, Hu Y, Zilioli S. 2020. Exogenous testosterone increases the audience  
566 effect in healthy males: evidence for the social status hypothesis. *Proceedings of the Royal*  
567 *Society B: Biological Sciences* **287**:20200976. doi:[10.1098/rspb.2020.0976](https://doi.org/10.1098/rspb.2020.0976)  
568
- 569 17. Terburg D, van Honk J. 2013. Approach–Avoidance versus Dominance–Submissiveness: A  
570 Multilevel Neural Framework on How Testosterone Promotes Social Status. *Emotion Review*  
571 **5**:296–302. doi:[10.1177/1754073913477510](https://doi.org/10.1177/1754073913477510)  
572
- 573 18. de Souza Silva MA, Mattern C, Topic B, Buddenberg TE, Huston JP. 2009. Dopaminergic  
574 and serotonergic activity in neostriatum and nucleus accumbens enhanced by intranasal  
575 administration of testosterone. *European Neuropsychopharmacology* **19**:53–63.  
576 doi:[10.1016/j.euroneuro.2008.08.003](https://doi.org/10.1016/j.euroneuro.2008.08.003)  
577
- 578 19. Hermans EJ, Bos PA, Ossewaarde L, Ramsey NF, Fernández G, van Honk J. 2010. Effects of  
579 exogenous testosterone on the ventral striatal BOLD response during reward anticipation in  
580 healthy women. *Neuroimage* **52**:277–283. doi:[10.1016/j.neuroimage.2010.04.019](https://doi.org/10.1016/j.neuroimage.2010.04.019)  
581
- 582 20. Op de Macks ZA, Moor BG, Overgaauw S, Güroğlu B, Dahl RE, Crone EA. 2011.  
583 Testosterone levels correspond with increased ventral striatum activation in response to  
584 monetary rewards in adolescents. *Developmental Cognitive Neuroscience*, Special Issue on  
585 Motivation **1**:506–516. doi:[10.1016/j.dcn.2011.06.003](https://doi.org/10.1016/j.dcn.2011.06.003)  
586
- 587 21. Sutton RS, Barto AG. 2018. Reinforcement Learning, second edition: An Introduction. MIT  
588 Press.  
589
- 590 22. Cohen JY, Haesler S, Vong L, Lowell BB, Uchida N. 2012. Neuron-type-specific signals for  
591 reward and punishment in the ventral tegmental area. *Nature* **482**:85–88.  
592 doi:[10.1038/nature10754](https://doi.org/10.1038/nature10754)  
593
- 594 23. Diederer K MJ, Spencer T, Vestergaard MD, Fletcher PC, Schultz W. 2016. Adaptive  
595 Prediction Error Coding in the Human Midbrain and Striatum Facilitates Behavioral  
596 Adaptation and Learning Efficiency. *Neuron* **90**:1127–1138.  
597 doi:[10.1016/j.neuron.2016.04.019](https://doi.org/10.1016/j.neuron.2016.04.019)  
598
- 599 24. Fontanesi L, Gluth S, Spektor MS, Rieskamp J. 2019. A reinforcement learning diffusion  
600 decision model for value-based decisions. *Psychon Bull Rev* **26**:1099–1121.  
601 doi:[10.3758/s13423-018-1554-2](https://doi.org/10.3758/s13423-018-1554-2)  
602
- 603 25. Geniole SN, Procyshyn TL, Marley N, Ortiz TL, Bird BM, Marcellus AL, Welker KM, Bonin  
604 PL, Goldfarb B, Watson NV, Carré JM. 2019. Using a Psychopharmacogenetic Approach To  
605 Identify the Pathways Through Which—and the People for Whom—Testosterone Promotes  
606 Aggression. *Psychol Sci* **30**:481–494. doi:[10.1177/0956797619826970](https://doi.org/10.1177/0956797619826970)  
607
- 608 26. Qu C, Ligneul R, Van der Henst J-B, Dreher J-C. 2017. An Integrative Interdisciplinary  
609 Perspective on Social Dominance Hierarchies. *Trends in Cognitive Sciences* **21**:893–908.  
610 doi:[10.1016/j.tics.2017.08.004](https://doi.org/10.1016/j.tics.2017.08.004)  
611
- 612 27. Carré JM, Geniole SN, Ortiz TL, Bird BM, Videto A, Bonin PL. 2017. Exogenous  
613 Testosterone Rapidly Increases Aggressive Behavior in Dominant and Impulsive Men. *Biol*  
614 *Psychiatry* **82**:249–256. doi:[10.1016/j.biopsych.2016.06.009](https://doi.org/10.1016/j.biopsych.2016.06.009)28. J. T. Cheng, J. L. Tracy, J.  
615 Henrich, Pride, personality, and the evolutionary foundations of human social status.  
616 *Evolution and Human Behavior* **31**, 334–347 (2010).

- 617  
618 28. Cheng JT, Tracy JL, Henrich J. 2010. Pride, personality, and the evolutionary foundations of  
619 human social status. *Evolution and Human Behavior* **31**:334–347.  
620 doi:[10.1016/j.evolhumbehav.2010.02.004](https://doi.org/10.1016/j.evolhumbehav.2010.02.004)  
621
- 622 29. Ratcliff R, McKoon G. 2008. The Diffusion Decision Model: Theory and Data for Two-  
623 Choice Decision Tasks. *Neural Comput* **20**:873–922. doi:[10.1162/neco.2008.12-06-420](https://doi.org/10.1162/neco.2008.12-06-420)  
624
- 625 30. Ahn W-Y, Haines N, Zhang L. 2017. Revealing Neurocomputational Mechanisms of  
626 Reinforcement Learning and Decision-Making With the hBayesDM Package. *Comput*  
627 *Psychiatr* **1**:24–57. doi:[10.1162/CPSY\\_a\\_00002](https://doi.org/10.1162/CPSY_a_00002)  
628
- 629 31. Zhang L, Lengersdorff L, Mikus N, Gläscher J, Lamm C. 2020. Using reinforcement learning  
630 models in social neuroscience: frameworks, pitfalls and suggestions of best practices. *Social*  
631 *Cognitive and Affective Neuroscience* **15**:695–707. doi:[10.1093/scan/nsaa089](https://doi.org/10.1093/scan/nsaa089)  
632
- 633 32. Dabbs JM. 1998. Testosterone and the concept of dominance. *Behavioral and Brain Sciences*  
634 **21**:370–371. doi:[10.1017/S0140525X98331222](https://doi.org/10.1017/S0140525X98331222)  
635
- 636 33. Mazur A, Booth A. 1998. Testosterone and dominance in men. *Behav Brain Sci* **21**:353–363;  
637 discussion 363-397.  
638
- 639 34. Daw ND, O’Doherty JP, Dayan P, Seymour B, Dolan RJ. 2006. Cortical substrates for  
640 exploratory decisions in humans. *Nature* **441**:876–879. doi:[10.1038/nature04766](https://doi.org/10.1038/nature04766)  
641
- 642 35. Aikey JL, Nyby JG, Anmuth DM, James PJ. 2002. Testosterone rapidly reduces anxiety in  
643 male house mice (*Mus musculus*). *Horm Behav* **42**:448–460. doi:[10.1006/hbeh.2002.1838](https://doi.org/10.1006/hbeh.2002.1838)  
644
- 645 36. Fernández-Guasti A, Martínez-Mota L. 2005. Anxiolytic-like actions of testosterone in the  
646 burying behavior test: role of androgen and GABA-benzodiazepine receptors.  
647 *Psychoneuroendocrinology* **30**:762–770. doi:[10.1016/j.psyneuen.2005.03.006](https://doi.org/10.1016/j.psyneuen.2005.03.006)  
648
- 649 37. H. Fan, S. J. Gershman, E. A. Phelps, Trait Somatic Anxiety is Associated With Reduced  
650 Directed Exploration and Underestimation of Uncertainty (2021)  
651 <https://doi.org/10.31234/osf.io/yx6sb> (November 15, 2021).  
652
- 653 38. Lenow JK, Constantino SM, Daw ND, Phelps EA. 2017. Chronic and Acute Stress Promote  
654 Overexploitation in Serial Decision Making. *J Neurosci* **37**:5681–5689.  
655 doi:[10.1523/JNEUROSCI.3618-16.2017](https://doi.org/10.1523/JNEUROSCI.3618-16.2017)  
656
- 657 39. Miyamoto Y, Yoo J, Levine CS, Park J, Boylan JM, Sims T, Markus HR, Kitayama S,  
658 Kawakami N, Karasawa M, Coe CL, Love GD, Ryff CD. 2018. Culture and Social Hierarchy:  
659 Self- and Other-Oriented Correlates of Socioeconomic Status across Cultures. *J Pers Soc*  
660 *Psychol* **115**:427–445. doi:[10.1037/pspi0000133](https://doi.org/10.1037/pspi0000133)  
661
- 662 40. Kitayama S, King A, Yoon C, Tompson S, Huff S, Liberzon I. 2014. The dopamine D4  
663 receptor gene (DRD4) moderates cultural difference in independent versus interdependent  
664 social orientation. *Psychol Sci* **25**:1169–1177. doi:[10.1177/0956797614528338](https://doi.org/10.1177/0956797614528338)  
665
- 666 41. Wibrál M, Dohmen T, Klingmüller D, Weber B, Falk A. 2012. Testosterone Administration  
667 Reduces Lying in Men. *PLOS ONE* **7**:e46774. doi:[10.1371/journal.pone.0046774](https://doi.org/10.1371/journal.pone.0046774)  
668
- 669 42. van Honk J, Will G-J, Terburg D, Raub W, Eisenegger C, Buskens V. 2016. Effects of  
670 Testosterone Administration on Strategic Gambling in Poker Play. *Sci Rep* **6**:18096.  
671 doi:[10.1038/srep18096](https://doi.org/10.1038/srep18096)

672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728

43. Henderson A, Thoelen G, Nadler A, Barraza J, Nave G. 2018. Testing the influence of testosterone administration on men’s honesty in a large laboratory experiment. *Sci Rep* **8**:11556. doi:[10.1038/s41598-018-29928-z](https://doi.org/10.1038/s41598-018-29928-z)
44. Eisenegger C, von Eckardstein A, Fehr E, von Eckardstein S. 2013. Pharmacokinetics of testosterone and estradiol gel preparations in healthy young men. *Psychoneuroendocrinology* **38**:171–178. doi:[10.1016/j.psyneuen.2012.05.018](https://doi.org/10.1016/j.psyneuen.2012.05.018)
45. WMA - The World Medical Association-WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects (June 29, 2021).
46. Lockwood PL, Apps MAJ, Valton V, Viding E, Roiser JP. 2016. Neurocomputational mechanisms of prosocial learning and links to empathy. *PNAS* **113**:9763–9768. doi:[10.1073/pnas.1603198113](https://doi.org/10.1073/pnas.1603198113)
47. R Core Team, *R: A Language and Environment for Statistical Computing* (R Foundation for Statistical Computing, 2020).
48. Bates D, Mächler M, Bolker B, Walker S. 2015. Fitting Linear Mixed-Effects Models Using lme4. *Journal of Statistical Software* **67**:1–48. doi:[10.18637/jss.v067.i01](https://doi.org/10.18637/jss.v067.i01)
49. den Ouden HEM, Daw ND, Fernandez G, Elshout JA, Rijpkema M, Hoogman M, Franke B, Cools R. 2013. Dissociable effects of dopamine and serotonin on reversal learning. *Neuron* **80**:1090–1100. doi:[10.1016/j.neuron.2013.08.030](https://doi.org/10.1016/j.neuron.2013.08.030)

729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782

**Supplementary Information for:**

**Testosterone eliminates strategic prosocial behavior**

Hana H. Kutlikova, Lei Zhang, Christoph Eisenegger, Jack van Honk, Claus Lamm

Corresponding author: Hana H. Kutlikova

Email: [hana.kutlikova@univie.ac.at](mailto:hana.kutlikova@univie.ac.at)

This PDF file includes:

Supplementary text

Supplementary information on the use of statistical software and functions

Supplementary analysis of hormone data

Supplementary information on computational modeling

Supplementary information on the analysis of the genetic data

Figure S1

Tables S1 to S3

SI References

Other supplementary materials for this manuscript include the following:

Data and codes can be accessed on: <https://osf.io/qr4ve/>

## 783 **Supplementary information on the use of statistical software and functions**

784 Statistical analysis was performed using the R statistical language<sup>1</sup> and the packages: lme4<sup>2</sup> for  
785 construction of general linear mixed models (GLMM) and generalized linear mixed model  
786 (GzLMM); car package<sup>3</sup> for construction of general linear models and computation of  $p$ -values based  
787 on Type III Wald chi-square tests; sjPlot package<sup>4</sup> for post-hoc tests of significant three-way  
788 interactions including odds ratios (ORs) and 95% confidence intervals (95% CIs); yarr<sup>5</sup> and ggplot2<sup>6</sup>  
789 packages for construction of plots.

790 Computational modeling was performed using Markov chain Monte Carlo with the statistical  
791 computing language Stan<sup>7</sup> while following the hBayesDM package<sup>8</sup>. Model comparison and  
792 evaluation were performed using the LOO package<sup>9</sup>.

793

## 794 **Supplementary analysis of hormone data**

### 795 *The effect of drug treatment on hormone levels.*

796 After data collection was complete, saliva samples were shipped on dry ice to Dresden LabService  
797 GmbH led by Clemens Kirschbaum, Germany. Liquid chromatography-tandem mass spectrometry  
798 was used to determine the hormonal levels. To examine the change of the hormonal levels throughout  
799 the experimental session, testosterone, cortisol, and estradiol levels were analyzed using GLMMs with  
800 the fixed factors drug treatment (testosterone/placebo), visibility (observed/private), time (baseline/1 h  
801 50 min after drug treatment/20 min after the end of the task/60 min after the end of the task), and  
802 participant's identity as a random intercept. Due to the non-normal distribution of residuals, hormonal  
803 data were log-transformed. Baseline hormonal levels did not significantly differ across experimental  
804 groups (all  $p$ s > .263, see Table S1). As expected, 1h 50 min after gel administration, we observed  
805 higher testosterone levels in the testosterone group ( $M_{\text{Sample2}} = 5014.10$  pg/mL, 95%CI [3866.10,  
806 6502.88]) compared to the placebo group ( $M_{\text{Sample2}} = 134.30$ , 95%CI [103.54, 175.92]); drug treatment  
807 x time:  $F(3,522.59) = 47.82$ ,  $p < .001$ ,  $\eta^2 = .423$ ), a difference that remained stable until the end of the  
808 experiment (see Figure S1).

809 Testosterone levels of two participants in the testosterone group decreased after the drug  
810 administration (Sample 1/Sample 2: 629.29/308.95 pg/mL and 350.76/294.76 pg/mL), while  
811 testosterone levels of one participant in the placebo group increased considerably (Sample 1/Sample  
812 2: 546.133/1099.08 pg/mL). These three participants were excluded from the analyses.

813 There were no effects of drug treatment on cortisol (drug treatment x time:  $F(3,550.23) = 0.149$ ,  $p$   
814 = .930) or estradiol levels (drug treatment x time:  $F(3,551.12) = 1.420$ ,  $p = .236$ ).

815 The observation condition did not significantly influence any hormonal levels (testosterone: visibility  
816 x time:  $F(3,520.88) = 1.528$ ,  $p = .206$ ; cortisol: visibility x time:  $F(3,520.6) = 0.9$ ,  $p = .441$ ; estradiol:  
817 visibility x time:  $F(3,521.37) = 1.699$ ,  $p = .166$ ).



818 ***Contamination of salivary samples.***

819 Out of a total of 192 baseline samples, we noted that 34 contained above normal testosterone levels,  
820 atypical for normal young men ( $> 2000$  pg/mL). All other baseline values were hormonally typical.  
821 The samples with abnormally high testosterone values appeared only in the participants, who later  
822 received testosterone treatment, not in the placebo group. Previous research<sup>10,11</sup> described similar  
823 abnormally high testosterone levels and attributed it to the testosterone contamination of the common  
824 surfaces (e.g., doorknobs, keyboards), excluding the option of physiological contamination. Based on  
825 their recommendation, we implemented a cleaning protocol that included the wearing of disposable  
826 sterile gloves, cleaning of keyboards, computer mice, tables, and doorknobs with an alcohol-based  
827 solution after each session. Although these precautions successfully prevented between-session  
828 contamination, we suspect that they still did not reliably impede within-session contamination of the  
829 saliva containers. For future studies, we, therefore, recommend even stricter sanitizing protocols and  
830 more careful handling of the saliva collection tubes and boxes, before, during, and also after sample  
831 collection.

832 In our sample, the abnormally high values were present only in the sessions where testosterone was  
833 administered, and this notwithstanding, the testosterone group showed a reliable testosterone increase  
834 after the drug administration in comparison to the placebo group. We, therefore, decided to retain the  
835 participants with contaminated baseline samples for the behavioral analyses, except for the analysis  
836 that includes baseline testosterone levels.

837 ***Interaction of baseline cortisol with testosterone effects on the correct choice and RLDDM***  
838 ***parameters.***

839 Previous research has shown that exogenous testosterone influences status-seeking behavior more  
840 strongly in individuals with low endogenous cortisol levels<sup>12,13</sup>. To examine whether cortisol  
841 interacted with testosterone's effect on correct choice and reinforcement learning drift diffusion  
842 model (RLDDM) parameters, we added log-transformed, mean-centered baseline cortisol values as a  
843 predictor in interaction with the other factors (recipient, drug treatment, visibility) to the GzLMM of  
844 correct choice and the GzLMMs of the RLDDM parameters (see Method in the main text). The  
845 analysis revealed no significant interaction of baseline cortisol levels with testosterone effect on  
846 correct choice (recipient x drug treatment x visibility x baseline cortisol:  $OR = 1.05$ ,  $CI = [0.98, 1.13]$ ,  
847  $p = .202$ ), positive learning rate (recipient x drug treatment x visibility x baseline cortisol:  $OR = 1.10$ ,  
848  $CI = [0.76, 1.59]$ ,  $p = .614$ ), negative learning rate (recipient x drug treatment x visibility x baseline  
849 cortisol:  $OR = 1.01$ ,  $CI = [0.97, 1.06]$ ,  $p = .550$ ), choice consistency (recipient x drug treatment x  
850 visibility x baseline cortisol:  $OR = 1.00$ ,  $CI = [1.00, 1.01]$ ,  $p = .213$ ) or decision threshold (recipient x  
851 drug treatment x visibility x baseline cortisol:  $OR = 1.01$ ,  $CI = [1.00, 1.02]$ ,  $p = .122$ ).

852

853

854



## 855 **Supplementary information on computational modeling**

### 856 ***Rescorla-Wagner (RW) model.***

857 We started with the simple Rescorla-Wagner<sup>14</sup> model as our baseline model. On each trial, the value  
858 ( $V_{c,t}$ ) of the chosen option was updated with the reward prediction error (RPE):

$$859 \quad V_{c,t} = V_{c,t-1} + \alpha (O_{t-1} - V_{c,t-1}), \quad (1)$$

860 where  $O_{t-1}$  was the received outcome, and  $\alpha$  ( $0 < \alpha < 1$ ) denoted the learning rate.

### 861 ***Reward-punishment (RP) model.***

862 Studies have suggested that individuals may have separate updates for positive and negative  
863 feedback<sup>15</sup>. Hence, we tested a reward-punishment model on top of the RW model:

$$864 \quad V_{c,t} = \begin{cases} V_{c,t-1} + \alpha^{\text{pos}} (O_{t-1} - V_{c,t-1}), & \text{if } O_{t-1} > 0 \\ V_{c,t-1} + \alpha^{\text{neg}} (O_{t-1} - V_{c,t-1}), & \text{otherwise} \end{cases}, \quad (2)$$

865 where  $\alpha^{\text{pos}}$  and  $\alpha^{\text{neg}}$  were the learning rates for positive and negative RPEs, respectively.

866 In both RW and RP, action values were converted to action probabilities using the softmax function.

867 Let A and B be the choice symbols per trial, the probability of choosing A was computed via the  
868 difference between  $V(A)$  and  $V(B)$ :

$$869 \quad p(A) = \frac{1}{1 + e^{\beta(-V_A - V_B)}}, \quad p(B) = 1 - p(A), \quad (3)$$

870 where  $\beta$  ( $\beta > 0$ ) was the inverse temperature that represented choice consistency. Higher  $\beta$  indicated  
871 that individuals' choices were more consistent with their value computation, where lower  $\beta$  indicated  
872 that individuals behaved more randomly. The action probability was then used to model participants'  
873 choice data with a categorical distribution:

$$874 \quad \text{choice}_t \sim \text{categorical}([p_t(A), p_t(B)]) \quad (4)$$

875

### 876 ***Drift diffusion model (DDM).***

877 The drift diffusion model (a.k.a., diffusion decision model<sup>16</sup>) was a widely used computational  
878 framework to model individuals' response times (RTs). In its canonical expression, DDM contained  
879 four parameters, namely, the drift rate ( $v$ ;  $v > 0$ ), the initial bias ( $z$ ;  $z > 0$ ), non-decision time ( $T$ ;  $0 < T$   
880  $\min(\text{RT})$ ), as well as the decision threshold ( $a$ ). For simplicity in learning tasks with abstract symbols,  
881 the initial bias  $z$  was fixed at 0.5. Trial-by-trial RTs was distributed according to the Wiener first  
882 passage time (WFPT<sup>17</sup>):

$$883 \quad RT_t \sim \text{wfpt}(a, T, z, v). \quad (5)$$

884

885

886 ***Reinforcement learning drift diffusion model (RLDDM).***

887 In value-based decision-making, individuals' RTs may vary as the function of trial-by-trial valuation,  
888 such that the larger the value difference between choice alternatives, the faster the RT. Therefore, a  
889 joint reinforcement learning drift diffusion model (RLDDM) framework has been proposed<sup>18,19</sup>,  
890 bridging RL and DDM. This approach provides more granularity than using RL or DDM alone<sup>19</sup>. In  
891 essence, the drift rate in DDM was characterized by the accuracy-coded value differences computed  
892 from the RL counterpart. This way, the drift rate was no more a constant parameter throughout the  
893 entire experiment, instead, it varied across trials (i.e.,  $v_t$ , instead of  $v$ ) according to the values  
894 computed from RL updates (in the present study, RW or RP). In the simplest RLDDM, trial-by-trial  
895 drift rates were constructed via a linear function of value difference:

896 
$$v_t = v_{\text{scaling}} (V_{\text{correct},t} - V_{\text{incorrect},t}), \quad (6)$$

897 where  $v_{\text{scaling}}$  ( $v_{\text{scaling}} > 0$ ) was the scaling parameter that quantified the impact of value difference. Note  
898 that we employed stimulus coding in our RLDDM, so that in Equation (6), the drift rate was always a  
899 function of the value difference between the correct (i.e., more rewarding, 75% reward probability)  
900 and the incorrect options (i.e., less rewarding, 25% reward probability), rather than between the  
901 chosen and unchosen options.

902

903 ***Reinforcement learning drift diffusion model with non-linear transformation (RLDDM-nonlin).***

904 There is evidence that a non-linear mapping between value difference and the drift rate could better  
905 capture individuals' RTs as opposed to a linear transformation<sup>19</sup>. This is likely because non-linear  
906 functions may provide more sensitivity, akin to the softmax function in choice models. We thus  
907 implemented an RLDDM-nonlin following:

908 
$$v_t = S[v_{\text{scaling}} (V_{\text{correct},t} - V_{\text{incorrect},t})], \quad (7)$$

909 with

910 
$$S(x) = 2 \cdot \frac{v_{\text{max}}}{1 + e^{-x}} - v_{\text{max}}, \quad (8)$$

911 where  $S(x)$  was a non-linear sigmoid function centered at 0, that convert  $x$  to lie between  $-v_{\text{max}}$  and  
912  $v_{\text{max}}$  ( $v_{\text{max}} > 0$ ). It is worth noting that  $v_{\text{max}}$  only affected the maximum value of the drift rate, whereas  
913  $v_{\text{scaling}}$ , as in Equation 6, established the trial-by-trial mapping between value difference and the drift  
914 rate.

915 In both RLDDM and RLDDM-nonlin, all other DDM parameters (i.e.,  $a$ ,  $T$ ,  $z$ ) were identical to the  
916 canonical DDM model, and RTs were distributed with *wfpt* using trial-by-trial drift rate ( $v_t$ ):

917 
$$RT_t \sim wfpt(a, T, z, v_t). \quad (9)$$

918 Note that, in all candidate models (Table S1), we introduced differential parameters for the within-  
919 subject condition of our experiment, namely, all parameters were separately modeled for the “self”  
920 and the “other” conditions.

921

### 922 *Model estimation.*

923 The model estimation and model selection procedures were largely similar to<sup>20</sup>. Hence, below we  
924 echoed these procedures from<sup>20</sup> to enhance reproducibility, with modifications that were specific to  
925 the current study.

926 In all models, we simultaneously modeled participants’ choice and RT, separately for each between-  
927 subject condition (i.e., placebo vs. testosterone; observed vs. private). Model estimations of all  
928 candidate models were performed with hierarchical Bayesian analysis (HBA)<sup>21</sup> using the statistical  
929 computing language Stan (7) in R. Stan utilizes a Hamiltonian Monte Carlo (HMC; an efficient  
930 Markov Chain Monte Carlo, MCMC) sampling scheme to perform full Bayesian inference and obtain  
931 the actual posterior distribution. We performed HBA rather than maximum likelihood estimation  
932 (MLE) because HBA provides much more stable and accurate estimates than MLE<sup>19</sup>. Following the  
933 approach in the “hBayesDM” package (8) for using Stan in the field of reinforcement learning, we  
934 assumed, for instance, that a generic individual-level parameter  $\varphi$  was drawn from a group-level  
935 normal distribution, namely,  $\varphi \sim \text{Normal}(\mu_\varphi, \sigma_\varphi)$ , with  $\mu_\varphi$  and  $\sigma_\varphi$  being the group-level mean and  
936 standard deviation, respectively. Both these group-level parameters were specified with weakly-  
937 informative priors<sup>21</sup>:  $\mu_\varphi \sim \text{Normal}(0, 1)$  and  $\sigma_\varphi \sim \text{half-Cauchy}(0, 1)$ . This was to ensure that the  
938 MCMC sampler traveled over a sufficiently wide range to sample the entire parameter space.  
939 Appropriate parameter transformations were applied to double-bounded parameters (e.g., learning  
940 rate,  $[0, 1]$ ) with the inverse probit function (i.e., cumulative distribution function of the standard  
941 normal distribution), and single-bounded parameters (e.g., drift rate,  $(0, +\infty)$ ) with the soft-plus  
942 function (i.e.,  $\ln(1 + e^x)$ ), respectively.

943

944 In HBA, all group-level parameters and individual-level parameters were simultaneously estimated  
945 through the Bayes’ rule by incorporating behavioral data. We fit each candidate model with four  
946 independent MCMC chains using 1,000 iterations after 1,000 iterations for the initial algorithm  
947 warmup per chain, which resulted in 4,000 valid posterior samples. The convergence of MCMC  
948 chains was assessed both visually (from the trace plot) and through the Gelman-Rubin  $\hat{R}$  Statistics<sup>22</sup>.  
949  $\hat{R}$  values of all parameters were smaller than 1.05 in the current study), which indicated adequate  
950 convergence.

951

952

953

954 ***Model selection and validation.***

955 For model comparison and model selection, we computed the Leave-One-Out information criterion  
956 (LOOIC) score per candidate model<sup>23</sup>. The LOOIC score provides the point-wise estimate (using the  
957 entire posterior distribution) of out-of-sample predictive accuracy in a fully Bayesian way, which is  
958 more reliable compared to information criteria using point-estimate (e.g., Akaike information  
959 criterion, AIC; deviance information criterion, DIC). By convention, a lower LOOIC score indicates  
960 better out-of-sample prediction accuracy of the candidate model. We selected the model with the  
961 lowest LOOIC as the winning model. We additionally performed Bayesian model averaging (BMA)  
962 with Bayesian bootstrap (33) to compute the probability of each candidate model being the best  
963 model. Conventionally, BMA probability of 0.8 (or higher) is a decisive indication.  
964 Moreover, given that model comparison provided merely relative performance among candidate  
965 models<sup>23</sup>, we then tested how well our winning model's posterior prediction was able to replicate the  
966 key features of the observed data (a.k.a., posterior predictive checks, PPCs). Since we only found an  
967 effect in choice data, we performed PPCs only for choices (excluding RTs). To this end, we applied a  
968 one-step-ahead PPC<sup>20,25</sup> that factored in participants' actual action and outcome sequences to generate  
969 predictions with the entire posterior MCMC samples. Specifically, we let the winning model generate  
970 choices as many times as the number of MCMC samples (i.e., 4,000 times) per trial per participant,  
971 and we analyzed the generated data the same way as we did for the observed data. We then assessed  
972 whether these analyses could reproduce the behavioral pattern in our behavioral analyses (Figure 4B,  
973 4D in the main text).

974

975 ***Simulations of optimal learning rates.***

976 To better understand the magnitude of the posterior learning rates, we performed simulations to obtain  
977 "optimal learning rates", and then compared the posterior parameters in relation to these optimal  
978 parameters (Figure 4A, 4C in the main text). Because there were two learning rates ( $\alpha^{\text{pos}}$  and  $\alpha^{\text{neg}}$ ), to  
979 reduce complexity, we fixed the inverse temperature parameter to be the corresponding group-level  
980 posterior mean in each condition. For each simulation, we took a small grid per parameter (0:0.01:1)  
981 and computed the choice accuracy across 16 trials (identical to the main experiment) for each  
982 combination of the parameters. Each simulation was repeated 1000 times to obtain stable results. We  
983 then considered the parameters that gave the highest choice accuracy as the optimal learning rates.

984

985 ***Analysis of the RLDDM parameters and their association with prosocial behavior.***

986 Next, we examined whether the behavioral pattern found in the analysis of the correct choice would  
987 be associated with differences in the individual model parameters.

988 As a first step, we tested the parameters of our validated winning model for the 3-way interaction  
989 effect of drug treatment, visibility, and type of recipient. There was no significant 3-way interaction in  
990 the positive learning rate ( $B = 1.03$ ,  $CI = [1.00, 1.06]$ ,  $p = .071$ ). The analysis of the negative learning

991 rate revealed a three-way interaction of drug treatment, visibility, and type of recipient ( $B = 1.07$ ,  $CI$   
992  $= [1.03, 1.11]$ ,  $p = .002$ ) so that the participants in the placebo group had a relatively lower negative  
993 learning rate for prosocial choices when being watched than in privacy (recipient x visibility  
994 interaction in the placebo group:  $B = 0.77$ ,  $CI = [0.61, 0.98]$ ,  $p = .034$ ). Conversely, in the testosterone  
995 group, observation (vs privacy) relatively increased the negative learning rate for prosocial choices  
996 (recipient x visibility interaction in testosterone group:  $B = 1.31$ ,  $CI = [1.04, 1.66]$ ,  $p = .021$ ; Figure  
997 2A). Moreover, the analysis of the choice consistency (inverse temperature parameter tau, described  
998 also in the main text) likewise showed a three-way interaction ( $B = 0.98$ ,  $CI = [0.97, 0.99]$ ,  $p < .001$ ).  
999 Placebo group participants had relatively higher consistency in choices made for the other (vs. self)  
1000 when being observed than in privacy (recipient x visibility interaction in the placebo group:  $B = 1.08$ ,  
1001  $CI = [1.05, 1.10]$ ,  $p < .001$ ). On the contrary, in the testosterone group, observation, compared to  
1002 privacy, decreased the consistency of choices made for the other (vs. self) (recipient x visibility  
1003 interaction in testosterone group:  $B = 0.94$ ,  $CI = [0.92, 0.97]$ ,  $p < .001$ ). When participants were  
1004 observed, testosterone, compared to placebo, diminished the relative consistency of prosocial choices  
1005 (recipient x treatment interaction in observed condition:  $OR = 0.87$ ,  $CI = [0.85, 0.89]$ ,  $p = .001$ ). In the  
1006 private condition, there was no evidence for such an effect (recipient x treatment interaction in private  
1007 condition:  $OR = 0.99$ ,  $CI = [0.97, 1.02]$ ,  $p = .605$ ).

1008 The analysis of the DDM threshold parameter revealed a three-way interaction as well ( $B = 1.01$ ,  $CI =$   
1009  $[1.00, 1.02]$ ,  $p < .001$ ; Figure 2C). Placebo group participants had a relatively higher threshold for  
1010 choices made for another (vs. self) when being observed than in privacy (recipient x visibility  
1011 interaction in placebo group:  $B = 1.03$ ,  $CI = [1.01, 1.05]$ ,  $p < .001$ ). Conversely, in the testosterone  
1012 group, observation, compared to privacy, decreased the amount of information required for choices  
1013 made for another (vs. self) (recipient x visibility interaction in testosterone group:  $B = 0.95$ ,  $CI =$   
1014  $[0.92, 0.98]$ ,  $p < .001$ ). When participants were observed, testosterone, compared to placebo,  
1015 decreased the relative threshold of prosocial choices (recipient x treatment interaction in observed  
1016 condition:  $B = 0.95$ ,  $CI = [0.92, 0.98]$ ,  $p < .001$ ). The analysis of the DDM drift-scaling parameter  
1017 revealed a three-way interaction ( $B = 0.83$ ,  $CI = [0.82, 0.84]$ ,  $p < .001$ ). Participants in both placebo  
1018 (recipient x visibility interaction in placebo group  $B = 0.92$ ,  $CI = [0.91, 0.93]$ ,  $p < .001$ ) and  
1019 testosterone group (recipient x visibility interaction in placebo group  $B = 0.77$ ,  $CI = [0.76, 0.78]$ ,  $p$   
1020  $< .001$ ) showed relatively lower drift scaling for choices made for another (vs. self) when being  
1021 observed than in privacy (recipient x visibility interaction in placebo group  $B = 0.92$ ,  $CI = [0.91,$   
1022  $0.93]$ ,  $p < .001$ ). When participants were observed, testosterone, compared to placebo, decreased the  
1023 relative drift scaling of prosocial choices (recipient x treatment interaction in observed group:  $B =$   
1024  $0.93$ ,  $CI = [0.92, 0.94]$ ,  $p < .001$ ).

1025 As a second step, we examined whether the RLDDM parameters that were impacted by testosterone  
1026 administration predict behavioral prosociality, measured by the difference between correct choices  
1027 made for other and self across the whole sample. Out of the five parameters, negative learning rate ( $B$

1028 = -8.82,  $CI = [-15.89, -1.75]$ ,  $p < .015$ ), choice consistency ( $B = 5.45$ ,  $CI = [3.71, 7.19]$ ,  $p < .001$ ), and  
1029 DDM threshold ( $B = 9.56$ ,  $CI = [0.33, 18.18]$ ,  $p < .043$ ) predicted prosociality, however only choice  
1030 consistency survived the Bonferroni correction for multiple comparisons ( $p < .01$ ). Altogether, as  
1031 reported in the main text, these results suggest that testosterone's impact on strategic prosocial  
1032 behavior (i.e., audience effect) is strongly linked to testosterone's effect on choice consistency  
1033 (inverse temperature parameter tau).

1034

1035 ***Analysis of the drift-scaling parameter and response times.***

1036 As specified in equation (7), on each trial  $t$ , the drift rate  $v_t$  was defined with a drift-scaling parameter,  
1037  $v_{\text{scaling}}$  that scales the value difference between the correct and incorrect symbol. Drift-scaling  
1038 parameter affects the curvature of the function: smaller values lead to a more linear mapping between  
1039 the value difference and the drift rate, and therefore less sensitivity to value differences.

1040 Drift scaling is conceptually linked to the speed of integration and response times<sup>16</sup>, we therefore  
1041 tested whether drift-scaling parameter predicted response times and found a significant association ( $B$   
1042 = 0.96,  $CI = [0.95, 0.98]$ ,  $p < .001$ ). However, contrary to correct choices, response times did not  
1043 differ across experimental groups (drug treatment:  $B = 1.01$ ,  $CI = [0.97, 1.04]$ ,  $p < .706$ ; visibility:  $B =$   
1044 1.02,  $CI = [0.99, 1.06]$ ,  $p < .211$ ; recipient:  $B = 0.99$ ,  $CI = [0.98, 1.01]$ ,  $p < .315$ ; drug treatment x  
1045 visibility x recipient:  $B = 1.01$ ,  $CI = [0.99, 1.01]$ ,  $p < .841$ ).

1046



1047 **Supplementary information on the analysis of genetic data**

1048

1049 Previous research suggested that testosterone may influence behavior through dopaminergic  
1050 pathways<sup>26</sup>. In humans, testosterone administration enhanced activation of the ventral striatum to  
1051 monetary rewards<sup>27</sup> and the enhancing effects of exogenous testosterone on competitive status-  
1052 seeking were more pronounced among individuals with a 9/10R compared to 10/10R genotype of the  
1053 dopamine transporter (DAT)<sup>28</sup>. The expression of DAT, which regulates striatal dopamine, is linked to  
1054 a 40 base-pair variable number tandem repeat polymorphism of the DAT1 gene<sup>29</sup>. Homozygous  
1055 10/10-repeat carriers of this polymorphism have higher DAT expression (i.e., lower striatal dopamine)  
1056 than heterozygous, 9-repeat variant, individuals<sup>30</sup>.  
1057 Testosterone's effects on status-seeking behavior have likewise been shown to be enhanced among  
1058 individuals with fewer CAG repeats in exon 1 of the androgen-receptor gene<sup>28,31</sup>. In-vitro  
1059 experimental work suggests that increasing the number of CAG repeats within the androgen receptor  
1060 (AR) gene reduces the receptor's transcriptional potential<sup>32</sup>. In other words, the efficiency of the  
1061 androgen receptors is negatively related to the CAG repeat<sup>33</sup>.

1062 We, therefore, tested whether testosterone effects on strategic prosociality depended on individual  
1063 differences in striatal dopamine, assessed by DAT1 polymorphism, and efficiency of ARs, assessed  
1064 by the CAG repeat polymorphism.

1065

1066 ***Genotyping of AR CAG repeat and DAT1 polymorphisms.***

1067 DNA was extracted from buccal swabs and isolated using a resin-based method with Chelex®100  
1068 (Sigma Aldrich, USA). For amplification of the CAG repeat polymorphism in exon 1 of the AR gene  
1069 primers forward - 5' GCGCGAAGTGATCCAGAAC 3' tagged with 6-carboxyfluorescein and  
1070 reverse - 5' CTCATCCAGGACCAGGTAGC 3', and for amplification of the DAT1-3'UTR  
1071 VNTR polymorphism primers forward - 5' GTCCTTGTGGTGTAGGGAAC 3' tagged with 6-  
1072 carboxyfluorescein and reverse - 5' CTGGAGGTCACGGCTCAAG 3' were used in PCR with 20 µL  
1073 reaction using 250 nmol/L final primer molarity. As PCR mastermix 5x Hot FIREPol Blend  
1074 Mastermix with 7.5 mM MgCl<sub>2</sub> (Solis Biodyne, Tartu, Estonia) was used in all amplifications.  
1075 The following PCR program was used: initial denaturation step at 95°C for 15 min, followed by 30  
1076 cycles each consisting of denaturation at 95°C for 30 s, annealing at 60°C for 30 s and polymerization  
1077 at 72°C for 1 min. The number of repeats of AR CAG STR and DAT1-3'UTR VNTR was analyzed  
1078 by fragment analysis using Sanger sequencing on ABI 3500 Genetic Analyzer (Applied Biosystems,  
1079 USA).

1080

1081 ***Interaction of DAT1 polymorphism with testosterone effects on the correct choice and RLDDM***  
1082 ***parameters.***

1083 There were no significant differences in the distribution of the genotype among our experimental  
1084 groups ( $\chi^2(6, N = 187) = 6.95, p = .326$ ). The 9/10R and the 10/10R genotypes accounted for most of



1085 the observed DAT1 genotypes in our sample (36% (N=66) and 56% (N=103), respectively), and we  
1086 thus used these two genotypes in the analyses by adding DAT1 polymorphisms as a predictor in  
1087 interaction with the other factors (recipient, drug treatment, visibility) to the GzLMM of correct  
1088 choice and the GzLMMs of the RLDDM parameters (see Method in main text). The analysis revealed  
1089 no significant interaction of DAT1 polymorphism with testosterone effect on correct choice (recipient  
1090 x drug treatment x visibility x DAT1:  $OR = 0.97$ ,  $CI = [0.91, 1.03]$ ,  $p = .307$ ), positive learning rate  
1091 (recipient x drug treatment x visibility x DAT1:  $B = 1.17$ ,  $CI = [0.70, 1.94]$ ,  $p = .555$ ), negative  
1092 learning rate (recipient x drug treatment x visibility x DAT1:  $B = 0.58$ ,  $CI = [0.29, 1.18]$ ,  $p = .133$ ),  
1093 choice consistency (recipient x drug treatment x visibility x DAT1:  $B = 0.96$ ,  $CI = [0.89, 1.03]$ ,  $p$   
1094  $= .266$ ) or decision threshold (recipient x drug treatment x visibility x DAT1:  $B = 1.00$ ,  $CI = [1.00,$   
1095  $1.00]$ ,  $p = .947$ ).

1096  
1097 ***Interaction of AR CAG repeat polymorphism with testosterone effects on the correct choice and***  
1098 ***RLDDM parameters.***


1099 Mean-centered CAG repeat lengths of AR gene in exon 1 were included as a predictor in interaction  
1100 with the other factors (recipient, drug treatment, visibility) to the GzLMM of correct choice and the  
1101 GzLMMs of the RLDDM parameters (see Method in the main text). The analysis revealed no  
1102 significant interaction of CAG repeat polymorphism with testosterone effect on correct choice  
1103 (recipient x drug treatment x visibility x CAG:  $OR = 1.00$ ,  $CI = [0.99, 1.02]$ ,  $p = .769$ ), positive  
1104 learning rate (recipient x drug treatment x visibility x CAG:  $B = 1.00$ ,  $CI = [1.00, 1.01]$ ,  $p = .329$ ),  
1105 negative learning rate (recipient x drug treatment x visibility x CAG:  $B = 1.01$ ,  $CI = [1.00, 1.02]$ ,  $p$   
1106  $= .092$ ), choice consistency (recipient x drug treatment x visibility x CAG:  $B = 1.00$ ,  $CI = [0.99,$   
1107  $1.01]$ ,  $p = .696$ ) or decision threshold (recipient x drug treatment x visibility x CAG:  $B = 1.01$ ,  $CI =$   
1108  $[1.00, 1.02]$ ,  $p = .122$ ).

1109  
1110 ***Interaction of trait dominance with testosterone effects on RLDDM parameters.***

1111 Mean-centered dominance scores<sup>34</sup> were included as a predictor in interaction with the other factors  
1112 (recipient, drug treatment, visibility) to the GzLMM of correct choice (reported in the main text) and  
1113 the GzLMMs of the RLDDM parameters. Contrary to the former, the latter analysis revealed no  
1114 significant interaction of dominance scores with testosterone effect RLDDM parameters: positive  
1115 learning rate (recipient x drug treatment x visibility x dominance:  $B = 1.01$ ,  $CI = [0.98, 1.04]$ ,  $p$   
1116  $= .546$ ), negative learning rate (recipient x drug treatment x visibility x dominance:  $B = 1.02$ ,  $CI =$   
1117  $[0.98, 1.07]$ ,  $p = .341$ ), choice consistency (recipient x drug treatment x visibility x dominance:  $B =$   
1118  $1.00$ ,  $CI = [1.00, 1.01]$ ,  $p = .229$ ), or decision threshold (recipient x drug treatment x visibility x  
1119 dominance:  $B = 1.00$ ,  $CI = [1.00, 1.00]$ ,  $p = .492$ ).

1120

1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137



1138 **Figure S1.** Testosterone levels during the experimental session. Error bars = Mean  $\pm$  (95%CI).  
1139

1140 **Table S1.** Summary statistics across experimental groups: Mean (95%CI), ANOVA

Drug treatment Visibility	Placebo		Testosterone		F	p
	Private	Observed	Private	Observed		
N	46	45	52	44		
Age	25.2 (24.0, 26.4)	24.5 (23.3, 25.7)	24.4 (23.3, 25.5)	25.2 (24.0, 26.4)	1.141	.236
Baseline testosterone [pg/mL]	143 (76.7, 209)	131 (64.5, 197)	221 (150.2, 293)	261 (172.1, 350)		
log	4.75 (4.52, 4.98)	4.71 (4.48, 4.94)	4.92 (4.67, 5.16)	4.97 (4.66, 5.28)	0.128	.721
Baseline cortisol [nmol/L]	2.84 (1.81, 3.87)	3.69 (2.66, 4.72)	3.92 (2.96, 4.88)	3.57 (2.52, 4.61)		
log	0.77 (0.52, 1.02)	1.00 (0.75, 1.25)	0.91 (0.68, 1.15)	0.86 (0.61, 1.11)	1.260	.263
Baseline estradiol [pg/mL]	3.68 (3.12, 4.23)	3.73 (3.17, 4.29)	3.77 (3.25, 4.30)	3.73 (3.16, 4.29)		
log	1.23 (1.09, 1.36)	1.19 (1.05, 1.33)	1.21 (1.08, 1.33)	1.22 (1.08, 1.36)	0.112	.739
CAG-repeat polymorphism	19.6 (18.5, 20.7)	19.9 (18.9, 21.0)	19.4 (18.4, 20.4)	19.4 (18.3, 20.4)	0.083	.773
Dominance	3.89 (3.62, 4.17)	4.02 (3.74, 4.30)	4.05 (3.79, 4.31)	3.84 (3.56, 4.12)	1.432	.232

1141

1142

1143

1144 **Table S2.** Model space and model evidence.

1145 RW, Rescorla-Wagner model; RP, reward-punishment model; DDM, drift diffusion model; RLDDM,  
 1146 reinforcement learning drift diffusion model; RLDDM-nonlinear, RLDDM with a non-linear  
 1147 transformation function; LOOIC leave-one-out information criterion (lower LOOIC value indicates  
 1148 better out-of-sample predictive accuracy); weight, model weight calculated with Bayesian model  
 1149 averaging using Bayesian bootstrap (higher model weight value indicates a higher probability of the  
 1150 candidate model to have generated the observed data). The winning model is highlighted in bold.

1151

Task condition		Placebo Observed		Placebo Private		Testosterone observed		Testosterone Private	
		LOOIC	Weight	LOOIC	Weight	LOOIC	Weight	LOOIC	Weight
Model space	DDM	9688	0	10697	0	9991	0	12427	0
	RW RLDDM	8365	0	9522	0	8925	0	11170	0
	RLDDM-nonlinear	8235	0	9395	0	8782	0	10903	0
Model space	DDM	9538	0	10493	0	9813	0	12199	0
	RP RLDDM	7878	0.006	8868	0.053	8444	0.002	10425	0.001
	<b>RLDDM-nonlinear</b>	<b>7832</b>	<b>0.994</b>	<b>8837</b>	<b>0.947</b>	<b>8352</b>	<b>0.998</b>	<b>10261</b>	<b>0.999</b>

1152

1153

1154 **Table S3.** Summary of parameters in the winning model.

1155 Note that all parameters were further separated for “self” versus “other”, hence for each between-  
 1156 subject condition, the winning model contained 14 parameters. The initial bias  $z$  in DDM was fixed at  
 1157 0.5.  $\min(\text{RT})$ , lowest response time from observed data.

1158

Component	Parameter	Meaning	Interpretation
RL	$0 < \alpha^{\text{pos}} < 1$	learning rate for updating positive reward prediction error	the learning rate weighs the effect of the reward prediction error in the value update; a higher (lower) learning rate means a faster (slower) value update from the most recent outcome
	$0 < \alpha^{\text{neg}} < 1$	learning rate for updating negative reward prediction error	
	$\beta > 0$	inverse temperature in softmax action selection function	choice consistency parameter, captures how much choices rely on the value updates
DDM	$v_{\text{max}} > 0$	maximum value of the drift rate in the non-linear function	defines the upper/lower boundaries in the sigmoid non-linear function
	$v_{\text{scaling}} > 0$	drift scaling that maps value difference into the drift rate	scales the effect of value difference between the choice options on the drift rate
	$a > 0$	decision threshold, i.e., the distance between choice alternatives	“the endpoint” of the evidence accumulation process, captures the amount of information necessary to make a decision
	$0 < T < \min(\text{RT})$	non-decision time	considered to capture sensory delay and/or movement initiation

1159

1160

1161 **SI References**

1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213

1. R Core Team. 2020. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
2. Bates D, Mächler M, Bolker B, Walker S. 2015. Fitting Linear Mixed-Effects Models Using lme4. *Journal of Statistical Software* **67**:1–48. doi:[10.18637/jss.v067.i01](https://doi.org/10.18637/jss.v067.i01)
3. Fox J, Weisberg S. 2019. An R Companion to Applied Regression, Third. ed. Thousand Oaks CA: Sage.
4. Lüdtke D. 2020. sjPlot: Data Visualization for Statistics in Social Science.
5. Phillips N. 2017. yarr: A Companion to the e-Book “YaRrr!: The Pirate’s Guide to R.”
6. Wickham H. 2016. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York.
7. Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M, Brubaker M, Guo J, Li P, Riddell A. 2017. Stan: A Probabilistic Programming Language. *Journal of Statistical Software* **76**:1–32. doi:[10.18637/jss.v076.i01](https://doi.org/10.18637/jss.v076.i01)
8. Ahn W-Y, Haines N, Zhang L. 2017. Revealing Neurocomputational Mechanisms of Reinforcement Learning and Decision-Making With the hBayesDM Package. *Comput Psychiatr* **1**:24–57. doi:[10.1162/CPSY\\_a\\_00002](https://doi.org/10.1162/CPSY_a_00002)
9. Vehtari A, Gelman A, Gabry J. 2017. Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC. *Statistics and Computing*, **27**, 1413–1432. doi: [10.1007/s11222-016-9696-4](https://doi.org/10.1007/s11222-016-9696-4)
10. Knight EL, McShane BB, Kutlikova HH, Morales PJ, Christian CB, Harbaugh WT, Mayr U, Ortiz TL, Gilbert K, Ma-Kellams C, Riečanský I, Watson NV, Eisenegger C, Lamm C, Mehta PH, Carré JM. 2020. Weak and Variable Effects of Exogenous Testosterone on Cognitive Reflection Test Performance in Three Experiments: Commentary on Nave, Nadler, Zava, and Camerer (2017). *Psychol Sci* **31**:890–897. doi:[10.1177/0956797619885607](https://doi.org/10.1177/0956797619885607)
11. Nave G, Nadler A, Zava D, Camerer C. 2017. Single-Dose Testosterone Administration Impairs Cognitive Reflection in Men. *Psychol Sci* **28**:1398–1407. doi:[10.1177/0956797617709592](https://doi.org/10.1177/0956797617709592)
12. Knight EL, Sarkar A, Prasad S, Mehta PH. 2020. Beyond the challenge hypothesis: The emergence of the dual-hormone hypothesis and recommendations for future research. *Hormones and Behavior*, 30th Anniversary of the Challenge Hypothesis **123**:104657. doi:[10.1016/j.yhbeh.2019.104657](https://doi.org/10.1016/j.yhbeh.2019.104657)
13. Mehta PH, Prasad S. 2015. The dual-hormone hypothesis: a brief review and future research agenda. *Current Opinion in Behavioral Sciences*, Social behavior **3**:163–168. doi:[10.1016/j.cobeha.2015.04.008](https://doi.org/10.1016/j.cobeha.2015.04.008)
14. R. A. Rescorla, A. R. Wagner, “A theory of Pavlovian conditioning: Variations in the effectiveness of reinforcement and nonreinforcement” in *Classical Conditioning II: Current Research and Theory*, (Appleton-Century-Crofts, 1972), pp. 64–99.

- 1214 15. den Ouden HEM, Daw ND, Fernandez G, Elshout JA, Rijpkema M, Hoogman M, Franke  
1215 B, Cools R. 2013. Dissociable effects of dopamine and serotonin on reversal learning.  
1216 *Neuron* **80**:1090–1100. doi:[10.1016/j.neuron.2013.08.030](https://doi.org/10.1016/j.neuron.2013.08.030)  
1217
- 1218 16. Ratcliff R, McKoon G. 2008. The Diffusion Decision Model: Theory and Data for Two-  
1219 Choice Decision Tasks. *Neural Comput* **20**:873–922. doi:[10.1162/neco.2008.12-06-420](https://doi.org/10.1162/neco.2008.12-06-420)  
1220
- 1221 17. Navarro DJ, Fuss IG. 2009. Fast and accurate calculations for first-passage times in Wiener  
1222 diffusion models. *Journal of Mathematical Psychology* **53**:222–230.  
1223 doi:[10.1016/j.jmp.2009.02.003](https://doi.org/10.1016/j.jmp.2009.02.003)  
1224
- 1225 18. Pedersen ML, Frank MJ, Biele G. 2017. The drift diffusion model as the choice rule in  
1226 reinforcement learning. *Psychon Bull Rev* **24**:1234–1251. doi:[10.3758/s13423-016-1199-y](https://doi.org/10.3758/s13423-016-1199-y)  
1227
- 1228 19. Fontanesi L, Gluth S, Spektor MS, Rieskamp J. 2019. A reinforcement learning diffusion  
1229 decision model for value-based decisions. *Psychon Bull Rev* **26**:1099–1121.  
1230 doi:[10.3758/s13423-018-1554-2](https://doi.org/10.3758/s13423-018-1554-2)  
1231
- 1232 20. Zhang L, Gläscher J. 2020. A brain network supporting social influences in human  
1233 decision-making. *Science Advances* **6**:eabb4159. doi:[10.1126/sciadv.abb4159](https://doi.org/10.1126/sciadv.abb4159)  
1234
- 1235 21. Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. 2015. Bayesian Data  
1236 Analysis, 3rd ed. New York: Chapman and Hall/CRC. doi:[10.1201/b16018](https://doi.org/10.1201/b16018)  
1237
- 1238 22. Gelman A, Rubin DB. 1992. Inference from Iterative Simulation Using Multiple  
1239 Sequences. *Statistical Science* **7**:457–472.  
1240
- 1241 23. Vehtari A, Gelman A, Gabry J. 2016. Practical Bayesian model evaluation using leave-one-  
1242 out cross-validation and WAIC. *arXiv:150704544 [stat]*. doi:[10.1007/s11222-016-9696-4](https://doi.org/10.1007/s11222-016-9696-4)  
1243
- 1244 24. Yao Y, Vehtari A, Simpson D, Gelman A. 2018. Using Stacking to Average Bayesian  
1245 Predictive Distributions (with Discussion). *Bayesian Analysis* **13**:917–1007.  
1246 doi:[10.1214/17-BA1091](https://doi.org/10.1214/17-BA1091)  
1247
- 1248 25. Zhang L, Lengersdorff L, Mikus N, Gläscher J, Lamm C. 2020. Using reinforcement  
1249 learning models in social neuroscience: frameworks, pitfalls and suggestions of best  
1250 practices. *Social Cognitive and Affective Neuroscience* **15**:695–707.  
1251 doi:[10.1093/scan/nsaa089](https://doi.org/10.1093/scan/nsaa089)  
1252
- 1253 26. Purves-Tyson TD, Owens SJ, Double KL, Desai R, Handelsman DJ, Weickert CS. 2014.  
1254 Testosterone Induces Molecular Changes in Dopamine Signaling Pathway Molecules in the  
1255 Adolescent Male Rat Nigrostriatal Pathway. *PLoS One* **9**:e91151.  
1256 doi:[10.1371/journal.pone.0091151](https://doi.org/10.1371/journal.pone.0091151)  
1257
- 1258 27. Hermans EJ, Bos PA, Ossewaarde L, Ramsey NF, Fernández G, van Honk J. 2010. Effects  
1259 of exogenous testosterone on the ventral striatal BOLD response during reward anticipation  
1260 in healthy women. *Neuroimage* **52**:277–283. doi:[10.1016/j.neuroimage.2010.04.019](https://doi.org/10.1016/j.neuroimage.2010.04.019)  
1261
- 1262 28. Losecaat Vermeer AB, Krol I, Gausterer C, Wagner B, Eisenegger C, Lamm C. 2020.  
1263 Exogenous testosterone increases status-seeking motivation in men with unstable low  
1264 social status. *Psychoneuroendocrinology* **113**:104552. doi:[10.1016/j.psyneuen.2019.104552](https://doi.org/10.1016/j.psyneuen.2019.104552)  
1265
- 1266 29. Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW, Uhl GR. 1992.  
1267 Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a  
1268 VNTR. *Genomics* **14**:1104–1106. doi:[10.1016/s0888-7543\(05\)80138-7](https://doi.org/10.1016/s0888-7543(05)80138-7)



- 1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289
30. Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, Gorey JG, Lee KS, Linnoila M, Weinberger DR. 2000. Genotype Influences In Vivo Dopamine Transporter Availability in Human Striatum. *Neuropsychopharmacol* **22**:133–139. doi:[10.1016/S0893-133X\(99\)00099-8](https://doi.org/10.1016/S0893-133X(99)00099-8)
  31. Geniole SN, Procyshyn TL, Marley N, Ortiz TL, Bird BM, Marcellus AL, Welker KM, Bonin PL, Goldfarb B, Watson NV, Carré JM. 2019. Using a Psychopharmacogenetic Approach To Identify the Pathways Through Which—and the People for Whom—Testosterone Promotes Aggression. *Psychol Sci* **30**:481–494. doi:[10.1177/0956797619826970](https://doi.org/10.1177/0956797619826970)
  32. Chamberlain NL, Driver ED, Miesfeld RL. 1994. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. *Nucleic Acids Res* **22**:3181–3186. doi:[10.1093/nar/22.15.3181](https://doi.org/10.1093/nar/22.15.3181)
  33. Zitzmann M, Nieschlag E. 2003. The CAG repeat polymorphism within the androgen receptor gene and maleness. *Int J Androl* **26**:76–83. doi:[10.1046/j.1365-2605.2003.00393.x](https://doi.org/10.1046/j.1365-2605.2003.00393.x)
  34. Cheng JT, Tracy JL, Henrich J. 2010. Pride, personality, and the evolutionary foundations of human social status. *Evolution and Human Behavior* **31**:334–347. doi:[10.1016/j.evolhumbehav.2010.02.004](https://doi.org/10.1016/j.evolhumbehav.2010.02.004)